Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
J Nanobiotechnology
; 19(1): 33, 2021 Jan 29.
Article
in English
| MEDLINE | ID: covidwho-1054825
ABSTRACT
BACKGROUND:
The outbreak and pandemic of coronavirus SARS-CoV-2 caused significant threaten to global public health and economic consequences. It is extremely urgent that global people must take actions to develop safe and effective preventions and therapeutics. Nanobodies, which are derived from singlechain camelid antibodies, had shown antiviral properties in various challenge viruses. In this study, multivalent nanobodies with high affinity blocking SARS-CoV-2 spike interaction with ACE2 protein were developed.RESULTS:
Totally, four specific nanobodies against spike protein and its RBD domain were screened from a naïve VHH library. Among them, Nb91-hFc and Nb3-hFc demonstrated antiviral activity by neutralizing spike pseudotyped viruses in vitro. Subsequently, multivalent nanobodies were constructed to improve the neutralizing capacity. As a result, heterodimer nanobody Nb91-Nb3-hFc exhibited the strongest RBD-binding affinity and neutralizing ability against SARS-CoV-2 pseudoviruses with an IC50 value at approximately 1.54 nM.CONCLUSIONS:
The present study indicated that naïve VHH library could be used as a potential resource for rapid acquisition and exploitation of antiviral nanobodies. Heterodimer nanobody Nb91-Nb3-hFc may serve as a potential therapeutic agent for the treatment of COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Single-Domain Antibodies
/
Spike Glycoprotein, Coronavirus
Limits:
Humans
Language:
English
Journal:
J Nanobiotechnology
Year:
2021
Document Type:
Article
Affiliation country:
S12951-021-00768-w
Similar
MEDLINE
...
LILACS
LIS